Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31

Executive Summary

Centocor sales representatives will visit 85% of targeted Remicade prescribers by the end of August to inform them of a new black box warning added to labeling for the rheumatoid arthritis therapy, Exec Director-Medical Affairs Tom Schaible, PhD, told the FDA Arthritis Advisory Committee.
Advertisement

Related Content

TNF inhibitor safety
TNF inhibitor safety
Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
TB Data Collection Should Include Concomitant Medications, Centocor Says
TB Data Collection Should Include Concomitant Medications, Centocor Says
Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.
Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.
Advertisement
UsernamePublicRestriction

Register

PS038364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel